Complete response letter for Theravance's Vibativ in nosocomial pneumonia
This article was originally published in Scrip
Executive Summary
The US FDA has issued Theravance a complete response letter for its antibiotic Vibativ (telavancin) for the treatment of nosocomial pneumonia.